MR CLEAN-R Registry

Rationale and Aim

After the success of the MR CLEAN trial, followed by the positive results from ESCAPE, EXTEND-IA, SWIFT-PRIME and REVASCAT, there is a momentum in endovascular treatment (EVT) for acute anterior circulation ischemic stroke in the Netherlands. With proof of a beneficial effect now available, the full implementation and integration of EVT in the Dutch health care system has started. The next logical question is: will the effectiveness and safety of EVT in routine clinical practice be similar as observed in the clinical trials?
The aim of the MR CLEAN Registry is to monitor implementation and safety of EVT in the Netherlands. We register all patients undergoing EVT, which includes patients treated in centers that started up after the MR CLEAN trials ended, and patients treated outside current indications.